ClinicalTrials.gg
RecruitingNCT07219654Updated Jun 18, 2026

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

A Phase 2 interventional study of TPX-115 and Cryopreserving hyaluronic acid medium in Partial Thickness Rotator Cuff Tears, sponsored by Tego Science, Inc.. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Tego Science, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 168 studies in Rotator Cuff Injuries with a site in United States — 40 open to participants now, 50 under way, none of them phase 3. Rotator Cuff Injuries · United States.

Planned enrollment
62nd of 130
60 · median 60
Started
2026
with 4 others
Phase 2
6 of 168
2 open now
Primary completion
2027-05
later than 26 of 49 live
Registered
162nd of 168
by date

Among the 168 studies in Rotator Cuff Injuries with a site in United States, this one is the 62nd largest by planned enrollment of the 130 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 26 of the 49 other live ones, and was the 162nd registered.

Rotator Cuff Injuries

631 studies on the registry are indexed under Rotator Cuff Injuries; 156 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

40 of the 168 studies in Rotator Cuff Injuries with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Rotator Cuff Injuries with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy and safety of allogeneic dermal fibroblasts (TPX-115) compared to placebo in patients with Partial-Thickness Rotator Cuff Tear(PTRCT).

Primary endpoint is to evaluate the efficacy of TPX-115 compared to placebo, as measured by improvement in the Constant-Murley Score (CMS) in patients with PTRCT.

Secondary endpoints are:

  • To evaluate functional (including shoulder pain) and structural improvements in the affected shoulder after administration of TPX-115 compared to placebo in patients with PTRCT
  • To evaluate the safety and tolerability of TPX-115 in patients with PTRCT
  • To assess the immunogenicity of TPX-115
03

Conditions studied

  • Partial Thickness Rotator Cuff Tears

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged >= 18 years.
  • Patients with PTRCT involving \<= 50% of the tendon thickness based on depth of defect (or Grade I or II on Ellman classification) assessed by MRI within the last 3 months prior to screening and determined by the investigator.
  • Patients with clinical symptoms including but not limited to pain, muscle weakness, or limited active range of motion (ROM) of PTRCT persisting for more than 3 months despite conservation treatment.
  • Patients who report a usual pain level of >= 4 on visual analogue scale (VAS) at screening.
  • Patients who had, in the opinion of the investigator, at least 1 reasonable physical therapy course and no substantial response within 6 months prior to enrollment.
  • Patients who are willing to discontinue all pain medications on the shoulder (except rescue medication of \< 3.25g acetaminophen per day) at least 72 hours prior to screening and throughout the duration of study.
  • Patients in general good health, with no concomitant conditions or taking treatments potentially representing confounding factors and interfering with the study treatment or study procedures and their results or putting the patient at a greater risk, as per the investigator's documented clinical judgment.
  • Patients who meet the following laboratory criteria, with results within 5% of the specified normal reference ranges:

    1. : 12 to 18 g/dL.
    2. White Blood Cell (WBC) Count: 4.5 to 11.0 x 10\^3/uL.
  • Patients with > 60 ml/min
  • Patients with and AST \< 3xUpper limit of normal
  • Patients who are willing and able to give written for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with full-thickness rotator cuff tear in the affected shoulder as assessed by MRI.
  • Patients with both partial- and full-thickness rotator cuff tear in the affected shoulder.
  • Patients who have experienced previous surgeries in the affected shoulder within 12 months prior to enrollment.
  • Patients who have received subacromial or intra-articular injection in the affected shoulder within 3 months prior to screening visit.
  • Patients who have a history of cell therapy or prolotherapy in the affected shoulder.
  • Patients who have received -rich plasma (PRP) injection in the affected shoulder within 6 months prior to screening visit.
  • Patients who have received systemic therapy within 4 weeks prior to screening visit.
  • Patients who have any of the following diseases at screening or have medical history of past:

    1. inflammatory joint disease (eg, septic arthritis, rheumatoid inflammation)
    2. other shoulder disease, in the affected shoulder, that may cause shoulder pain or functional disorder (eg, arthritis, cervical spine disorders, subacromial pathological morphology leading to impingement syndrome)
    3. disease
    4. active or C (except for simple carriers and hepatitis B patients with antiviral medications for 6 months before screening)
    5. antibody-positive
    6. history of systemic within the last 5 years
    7. coagulopathy
    8. genetic disorders affecting fibroblasts or collagen production (eg. achondroplasia, osteogenesis imperfecta)
    9. other serious diseases (eg. neurological cardiovascular, renal or hepatic disease, uncontrolled diabetes, etc) that, inthe opinion of the investigator, might confound study results or pose additional risk to the patient by their participation in the study.
  • Female patients who are pregnant or breastfeeding.
  • Female patients planning pregnancy during the study period. Women of who do not agree to maintain , or who do not agree to use the appropriate method of contraception (ie, double effective barrier contraception) during the study period.

Note: Suitable contraceptive methods are condom, sponge, gel, diaphragm for contraception, hormonal contraceptives, intrauterine device, etc. Periodic abstinence (eg, calendar method, ovulation method, symptom body temperature method, post-ovulation method) and restraint are not considered an accepted method of contraception. However, women unable to become pregnant due to menopause (at least 12 months since last menstrual period) can participate in the study with negative pregnancy test results.

  • Patients who have administered other IPs or devices within 4 weeks or 5 half-lives, whichever is greater, prior to the IP administration.
  • Patients whom the principal investigator considers inappropriate for the study due to any other reasons than those listed above.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    TPX-115 low dose

    Biological: TPX-115

  • Experimental
    TPX-115 medium dose

    Biological: TPX-115

  • Experimental
    TPX-115 high dose

    Biological: TPX-115

  • Experimental
    Cryopreserving hyaluronic acid medium

    Other: Cryopreserving hyaluronic acid medium

  • Placebo comparator
    saline

    Drug: Saline

Interventions

  • BiologicalTPX-115

    Single injection of Allogeneic dermal fibroblasts (TPX-115) via ultrasound-guided intratendinous injection

  • OtherCryopreserving hyaluronic acid medium

    Medium included in TPX-115 for cryopreservation

  • DrugSaline

    Saline

06

What researchers measure

Primary outcomes

  1. Change from baseline in Constant-Murley Score(CMS) at Week 24

    The CMS is calculated from 0 (worst function) to 100 (best function) points

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change from baseline in Constant-Murley Score(CMS) at Weeks 4, 12, and 52

    The CMS is calculated from 0 (worst function) to 100 (best function) points

    Time frame: Baseline, Week 4, Week 12, Week 52

  2. Increase of at least 8 points from baseline in Constant-Murley Score(CMS) at Week 24

    The CMS is calculated from 0 (worst function) to 100 (best function) points

    Time frame: Baseline, Week 24

  3. Change from baseline in Visual Analogue Scale(VAS) (0 to 10 cm) score for shoulder pain at Weeks 4, 12, 24, and 52

    The VAS is a horizontal line, 10 cm in length, with anchor statements on the left (0 cm; meaning 'no pain') and on the right (10cm; meaning 'extreme pain')

    Time frame: Baseline, Week 4, Week 12, Week 24, Week 52

  4. Change from baseline in Range of Motion(ROM) in the affected shoulder at Weeks 4, 12, 24, and 52

    Time frame: Baseline, Week 4, Week 12, Week 24, Week 52

  5. Change from baseline in American Shoulder and Elbow Surgeons(ASES) score at Weeks 4, 12, 24, and 52

    The ASES score is calculated from zero (worst) to 100 (best) points

    Time frame: Baseline, Week 4, Week 12, Week 24, Week 52

  6. Change from baseline in Simple Shoulder Test at Weeks 4, 12, 24, and 52

    Time frame: Baseline, Week 4, Week 12, Week 24, Week 52

  7. Change from baseline in tear size (mm) on MRI at Week 52

    Time frame: Baseline, Week 52

  8. Change from baseline in tendon thickness (mm) on MRI at Week 52

    Time frame: Baseline, Week 52

  9. Change from baseline in tear/footprint (%p) on MRI at Week 52

    Time frame: Baseline, Week 52

  10. Change from baseline in tendinosis on MRI at Week 52

    The grade of tendinosis is assessed from zero (normal) to 3 (marked) by a central reader only (independent evaluator).

    Time frame: Baseline, Week 52

07

Study locations

2 of 3 sites recruiting
  • BioSolutions Clinical Research Center
    La Mesa, California 92262, United States
    Recruiting
  • Sports & Orthopedic Center - Advanced Research
    Deerfield Beach, Florida 33064, United States
    Active, not recruiting

    Not enrolling at this site.

  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Oct 22, 2025
StartActual
Jun 9, 2026
Primary completionEst.
May 2027
CompletionEst.
Nov 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219654
Lead sponsor
Tego Science, Inc.
Responsible party
Sponsor
First posted
Oct 22, 2025
Start date
Jun 9, 2026
Primary completion
May 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jun 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TPX-115

Start the discussion